Neurofibromatosis type 2
- aDepartment of Medical Genetics, St Mary's Hospital, Hathersage Road, Manchester M13 0JH, UK, bFinnish Institute of Occupational Health, Tapeliuksenkato 41, FIN-00250 Helsinki, Finland, cLos Angeles, California
- Dr Evans,gevans{at}central.cmht.nwest.nhs.uk
Abstract
Neurofibromatosis type 2 is an often devastating autosomal dominant disorder which, until relatively recently, was confused with its more common namesake neurofibromatosis type 1. Subjects who inherit a mutated allele of the NF2 gene inevitably develop schwannomas, affecting particularly the superior vestibular branch of the 8th cranial nerve, usually bilaterally. Meningiomas and other benign central nervous system tumours such as ependymomas are other common features. Much of the morbidity from these tumours results from their treatment. It is now possible to identify theNF2 mutation in most families, although about 20% of apparently sporadic cases are actually mosaic for their mutation. As a classical tumour suppressor, inactivation of theNF2 gene product, merlin/schwannomin, leads to the development of both NF2 associated and sporadic tumours. Merlin/schwannomin associates with proteins at the cell cytoskeleton near the plasma membrane and it inhibits cell proliferation, adhesion, and migration.
